Literature DB >> 26202607

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.

Elisa Rumi1, Jelena D Milosevic2, Dominik Selleslag3, Ilaria Casetti4, Els Lierman5, Daniela Pietra6, Chiara Cavalloni4, Marta Bellini4, Chiara Milanesi6, Irene Dambruoso6, Cesare Astori6, Robert Kralovics2,7, Peter Vandenberghe5, Mario Cazzola6,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26202607     DOI： 10.1007/s00277-015-2451-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  11 in total

Review 1.  Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options.

Authors:  Paneez Khoury; Bruce S Bochner
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Sep - Oct

Review 2.  Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.

Authors:  Melanie C Dispenza; Bruce S Bochner
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 3.  Updates on eosinophilic disorders.

Authors:  Alexandar Tzankov; Kaaren K Reichard; Robert P Hasserjian; Daniel A Arber; Attilio Orazi; Sa A Wang
Journal:  Virchows Arch       Date:  2022-09-07       Impact factor: 4.535

4.  Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract.

Authors:  Ayush Sharma; Naoki Oishi; Rebecca L Boddicker; Guangzhen Hu; Hailey K Benson; Rhett P Ketterling; Patricia T Greipp; Darlene L Knutson; Sara M Kloft-Nelson; Rong He; Bruce W Eckloff; Jin Jen; Asha A Nair; Jaime I Davila; Surendra Dasari; Konstantinos N Lazaridis; N Nora Bennani; Tsung-Teh Wu; Grzegorz S Nowakowski; Joseph A Murray; Andrew L Feldman
Journal:  Blood       Date:  2018-03-28       Impact factor: 25.476

5.  Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Signe Spetalen; Assia Bassarova; Klaus Beiske; Francesca Micci; Sverre Heim
Journal:  Oncotarget       Date:  2017-10-10

6.  Ruxolitinib found to cause eyelash growth: a case report.

Authors:  Julia Song; Alice Song; Trisa Palmares; Michael Song; Harold Song
Journal:  J Med Case Rep       Date:  2017-07-12

7.  Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia.

Authors:  Giuliana Rizzuto; Matteo Leoncin; Silvia Imbergamo; Daniela Taurino; Maria Caterina Mico; Manuela Tosi; Anna Michelato; Ksenija Buklijas; Orietta Spinelli; Federico Lussana; Federica Lessi; Marco Pizzi; Laura Bonaldi; Gianni Binotto; Alessandro Rambaldi; Carmela Gurrieri
Journal:  Clin Case Rep       Date:  2022-01-07

Review 8.  Approach to Eosinophilia Presenting With Pulmonary Symptoms.

Authors:  Chen E Rosenberg; Paneez Khoury
Journal:  Chest       Date:  2020-09-28       Impact factor: 9.410

Review 9.  JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.

Authors:  William Vainchenker; Emilie Leroy; Laure Gilles; Caroline Marty; Isabelle Plo; Stefan N Constantinescu
Journal:  F1000Res       Date:  2018-01-17

10.  The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and ZBTB20-JAK2 gene fusion presenting as B-lymphoblastic leukemia.

Authors:  Winston Y Lee; Ruthann B Pfau; Sarah M Choi; Jiong Yang; Hong Xiao; Eileen M Putnam; Russell Jh Ryan; Dale L Bixby; Lina Shao
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.